E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Biological Phenomena [G16] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of different dose levels of ARA 290 administration on different outcome measures of small fiber neuropathy in subjects with sarcoidosis. |
|
E.2.2 | Secondary objectives of the trial |
Assess changes in small fiber neuropathy score and Brief Pain Inventory |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Established diagnosis of sarcoidosis with both of the following two criteria: 1) Score of of 4 or greater on Brief Pain Inventory “average pain” questions (BPI; 0 (least discomfort)-10 (worst discomfort)) 2) Discomfort defined as distal pain/discomfort plus one of the following: 1) dysesthesia, 2) burning/painful feet worsening at night, or 3) intolerance of sheets or clothes touching the legs or feet
AND either of the following two criteria 1) Corneal nerve fiber density reduced compared to normal (i.e., greater than 1 standard deviation less than the mean of a normative population) 2) A previous skin biopsy (obtained within the prior 2 years) showing a reduced intraepidermal nerve fiber density ((i.e., greater than 1 standard deviation less than the mean of a normal age and gender relevant population)
Be able to read and understand the written consent form, complete study-related procedures, and communicate with the study staff Be willing to comply with study restrictions Be willing to check in with the study center via the telephone Between 18 and 70 years of age (inclusive) Body Mass Index (BMI) < 40 kg/m2 (inclusive) If female of childbearing potential, a negative urine pregnancy test at screening and acceptable contraception will be maintained during the screening and dosing period and 1 month beyond. Acceptable contraception consists of hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the subject’s usual menstrual cycle period) before study entry, intrauterine device (IUD), or double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream). Able to complete self-administered questionnaires (RAND-36, SFNSL, BPI, COMPASS-31, NPSI) Refrigerator and freezer at home for storage of study medication.
|
|
E.4 | Principal exclusion criteria |
Medical history of clinically relevant physical and mental health condition other than conditions related to sarcoidosis, as judged by the investigator Clinically relevant abnormal laboratory results, vital signs, or physical findings other than conditions related to sarcoidosis or could interfere with conduct of 6-minute walk assessment (as judged by the investigator) Other medical conditions known to be associated with small nerve fiber loss, except for diabetes in good control (as judged by the investigator) Known clinically relevant abnormalities in ECG (as judged by the investigator) Illicit drug abuse or excessive alcohol consumption (as judged by the investigator) History of serious malignancy within the last 5 years other than a basal cell or squamous cell carcinoma that has been removed. History of severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food that could compromise the safety of the patient History of severe reaction in the past to Candida or Mumps antigens Anti-TNF therapy or other biological anti-inflammatory agents administered within the 6 months prior to screening. Use of erythropoiesis stimulating agents within the two months prior to screening or during the trial Participation in an investigational drug trial in the 3 months prior to administration of the initial dose of study drug or more than 4 times in the calendar year preceding study enrollment Inadequate venous accessibility as judged by study personnel Inability or unwillingness to self-administer ARA 290 via subcutaneous injections (or not have access to home health care for assistance in administration, if needed) If female, pregnant or breast-feeding Any other condition that in the opinion of the investigator would complicate or compromise the study, or the well-being of the subject |
|
E.5 End points |
E.5.1 | Primary end point(s) |
change in corneal nerve fiber density |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
at day 28 versus baseline |
|
E.5.2 | Secondary end point(s) |
Change in IENFD of an ankle biopsy at 28 days versus baseline Change in the scores of the Small Fiber Neuropathy Screening List, BPI, NPSI, RAND-36, and COMPASS-31 at days 28 and 56 compared to baseline Change in the 6 minute walk test at day 28 versus baseline Change in the scores of the Small Fiber Neuropathy Screening List, BPI, NPSI, RAND-36, and COMPASS-31 at days 70, 84, 98 and 112 compared to days 28, 56 and baseline (persistence of effect) Frequency of adverse events, serious adverse events, and laboratory parameters
Exploratory endpoints: Change in quantitative sensory testing (QST) at day 28 versus baseline Change in cardiac autonomic function (heart rate variability; R-R and QT intervals) at day 28 versus baseline as measured by Cardiac Autonomic Reflex Testing (CART) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Change at day 28 versus baseline and changes at days 56, 70, 84, 98, and 112 compared to baseline and day 28 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS The study will end prematurely in case the investigators in close cooperation with the ethics committee decide this. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |